Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate
New England Journal of Medicine · 06.11.2025 · 393 (18) · 1807-1818
DOI: 10.1056/nejmoa2501073 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 06.11.2025. Verfasst von Elissa Malkin und 43 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research Unit, George Washington University, Washington, DC. Hauptthemen laut MEDLINE: Immunogenicity, Vaccine, Lassa Fever, Lassa virus, Viral Vaccines. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Coalition for Epidemic Preparedness Innovations.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vaccine Research Unit, George Washington University, Washington, DC.
- International AIDS Vaccine Initiative (IAVI) Human Immunology Laboratory, Imperial College London, London.
- IAVI, New York.
- Partnership for Research on Vaccines and Infectious Diseases in Liberia, Monrovia.
- Brigham and Women's Hospital, Boston.
- East-West Medical Research Institute, Honolulu.
ORCID-Profile: Natalia Fernandez, Ruhani Varma
Förderung
- NCI NIH HHS
- NIH HHS
- Coalition for Epidemic Preparedness Innovations
Zitieren
APA
Malkin, E., Zaric, M., Kieh, M., Baden, L. R., Fitz-Patrick, D., Marini, A., Yun, H., Hayes, P., Bromell, R., Ayorinde, M., Fernandez, N., Varma, R., Sigei, F., Ward, M., Pindolia, H., Sewell, S., Amini, F., Blie, J., Wilson, B., …, & rVSVΔG-LASV-GPC Study Group (2025). Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate. New England Journal of Medicine, 393(18), 1807-1818. https://doi.org/10.1056/nejmoa2501073
Vancouver
Malkin E, Zaric M, Kieh M, Baden LR, Fitz-Patrick D, Marini A, et al. Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate. New England Journal of Medicine. 2025;393(18):1807-1818. doi:10.1056/nejmoa2501073
BibTeX
@article{Malkin2025,
author = {Malkin, Elissa and Zaric, Marija and Kieh, Mark and Baden, Lindsey R and Fitz-Patrick, David and Marini, Arianna and Yun, Heejin and Hayes, Peter and Bromell, Rachel and Ayorinde, Morolayo and Fernandez, Natalia and Varma, Ruhani and Sigei, Faith and Ward, Matthew and Pindolia, Hema and Sewell, Shayna and Amini, Fahimah and Blie, Julie and Wilson, Barthalomew and Faley, Patrick and McCullough, John and Tokpah, Franklin and Wisseh, Cecelia and Towalid, Elvis and Hadawale, Swapnil and Sayeed, Eddy and Hunt, Devin and Keshavarzi, Nahid and Barin, Burc and Maljkovic Berry, Irina and Parks, Christopher L and Truter, Shobhna Gopal and Walker, Kathleen and Vekemans, Johan and Lehrman, Jennifer and Engelbrecht, Michelle and Malherbe, Mariette and Laufer, Dagna and Philiponis, Vincent and Higgs, Elizabeth and Mutua, Gaudensia and Fast, Patricia E and Gupta, Swati B and rVSVΔG-LASV-GPC Study Group, rVSVΔG-LASV-GPC Study Group},
title = {Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {18},
pages = {1807--1818},
doi = {10.1056/nejmoa2501073}
}
EUVIMED